Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Derm Pharm 2020 > 2 - Azathioprine > Flashcards

2 - Azathioprine Flashcards

1
Q

Azathioprine was synthesised from its parent drug 6-mercaptopurine

A

True (AZA is a prodrug which is then rapidly converted into 6-MP in erythrocytes once it is absorbed from the GI tract)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Azathioprine has immunosuppressant but also anti-inflammatory properties

A

True (drug of choice for organ transplantation during the 1960s and 1970s)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prior to starting Azathioprine, thiopurine methyltransferase (TPMT) testing may help guide proper dosing and prevent catastrophic myelosuppression

A

True (genetic polymorphisms of TPMT exists)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Myelosuppression is an adverse effect of AZA

A

True (FBC is needed to monitor for myelosuppression throughout the course of treatment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hepatotoxicity is an adverse effect of AZA

A

True (LFTs are needed to monitor for hepatotoxicity throughout the course of treatment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GI symptoms is an adverse effect of AZA

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hypersensitivity reaction is an adverse effect of AZA

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Infections is an adverse effect of AZA

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pancreatitis is an adverse effect of AZA

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lymphoproliferative malignancy is an adverse effect of AZA

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cutaneous SCC is an adverse effect of AZA

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AZA dosing can be based on TPMT level

A

True (high TPMT = up to 2-2.5mg/kg daily, medium TPMT = up to 1mg/kg daily, low TPMT = do not use AZA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

88% of orally administered AZA is absorbed through the GI tract

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AZA does not cross the blood brain barrier

A

True (but crosses the placenta)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

AZA crosses the placenta

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AZA is rapidly and extensively metabolised

A

True (reaches peak plasma levels in < 2 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

AZA reaches peak plasma levels in < 2 hours

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

6-Thioguanine is the active metabolite of AZA which is converted from 6-MP via the hypoxanthine guanine phosphoribosyltransferase (HGPRT) anabolic pathway

A

True

AZA (prodrug) > 6-MP > 6-TG (active metabolite through HGPRT anabolic pathway)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

6-Thioguanine (active metabolite of AZA) slowly accumulates in tissues and slowly provides maximal clinical immunosuppression at around 8-12 weeks

A

True

AZA (prodrug) > 6-MP > 6-TG (active metabolite through HGPRT anabolic pathway)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

30% of of AZA is protein bound

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Upon absorption, AZA is rapidly converted to 6-mercaptopurine (6-MP) in the erythrocytes

A

True (AZA is a prodrug)

AZA (prodrug) > 6-MP > 6-TG (active metabolite through HGPRT anabolic pathway)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

AZA is a prodrug which is then converted to 6-MP in erythrocytes

A

True

AZA (prodrug) > 6-MP > 6-TG (active metabolite through HGPRT anabolic pathway)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

There are 3 metabolic pathways of AZA

A

True (2 pathways that yield inactive non-toxic metabolites and 1 anabolic pathway that yields active metabolites)

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

The 2 metabolic pathways of AZA that yield inactive non-toxic metabolites are the TPMT pathway and the xanthine oxidase pathway

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

The AZA anabolic pathway leads to active metabolites including 6-TG

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Both AZA degradation pathways lead to inactive non-toxic metabolites

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Reduced activity of 1 of the 2 AZA TPMT or xanthine oxidase degradative pathways will shift more 6-MP into the anabolic HGPRT pathway, leading to excessive clinical immunosuppression with an increased risk of myelosuppression

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

TPMT enzyme activity is reduced or absent in certain patients with a genetic polymorphism

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

The 3 TPMT (degradative) enzyme activity patient groups are patients with (1) high activity, (2) intermediate activity, and (3) low activity

A

True (patients with low TPMT enzyme degradative activity have markedly increased accumulation of 6-TG active metabolites as more 6-MP is shifted to the anabolic HGPRT pathway, which increases the risk of myelosuppression and this patient group should not receive AZA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Patients with low TPMT enzyme degradative activity have markedly increased accumulation of 6-TG active metabolites as more 6-MP is shifted to the anabolic HGPRT pathway, which increases the risk of myelosuppression and this patient group should not receive AZA

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
31
Q

Patients with high TPMT enzyme degradative activity may be therapeutically under-dosed as less 6-MP goes into the anabolic HGPRT pathway

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
32
Q

The TPMT enzyme function test measures the activity of TPMT in red blood cells and has been shown to correlate well with systemic TPMT activity

33
Q

AZA is virtually completely metabolised

A

True (therefore negligible unmetabolised AZA is excreted)

34
Q

Decreased activity of xanthine oxidase occurs as a result of allopurinol as a drug interaction

A

True (therefore allopurinol inhibits the xanthine oxidase degradative pathway and co-administration of allopurinol with AZA results in increased production of 6-TG active metabolites as more 6-MP is shifted to the anabolic HGPRT pathway, with excessive immunosuppression and increased risk for myelosuppression)

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
35
Q

Lesch-Nyhan syndrome affects the anabolic HGPRT pathway and the efficacy of AZA in these individuals

A

True

  1. TPMT Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  2. Xanthine oxidase Inactive pathway = AZA > 6-MP > degraded to inactive non-toxic metabolites
  3. Hypoxanthine guanine phosphoribosyltransferase anabolic pathway = AZA > 6-MP > anabolised to active 6-TG
36
Q

AZA’s active metabolite 6-TG’s structural similarity to the endogenous purines allows it to be incorporated into DNA and RNA, inhibiting purine metabolism and cell division

A

True (AZA also affects T cell and B cell function)

37
Q

AZA affects T cell and B cell function

A

True (the altered B cell antibody production is of central importance to AZA therapy for immunobullous dermatoses such as Pemphigus vulgaris and bullous pemphigoid)

38
Q

Pregnancy is an absolute contraindication for AZA

39
Q

Active clinically significant infections is an absolute contraindication for AZA

A

True (AZA is immunosuppressive)

40
Q

Prior use of alkylating agents is a relative contraindication for AZA use due to the theoretical increased malignancy risk

41
Q

Allopurinol is a relative contraindication for AZA use as it interacts/inhibits xanthine oxidase which has a role in the xanthine oxidase degradation pathway of 6-MP which shifts more 6-MP towards the anabolic HGPRT pathway causing increased 6-TG active metabolites contributing to the immunosuppressive and myelosuppressive effect of AZA

42
Q

AZA is contraindicated in patients with low TPMT enzyme activity

A

True (increased risk of AZA toxicity with immunosuppression and myelosuppression)

43
Q

AZA may cause lymphoproliferative malignancies (especially non-Hodgkins B-cell lymphomas) and SCC of the skin

A

True (although the increased incidence of these malignancies have not been convincingly demonstrated in dermatology patients, regular physical examination with attention to detection of these malignancies in patients on long term AZA are important)

44
Q

Severe myelosuppression is a rare adverse event resulting from excessive immunosuppression by AZA, including at relatively low dosages in patients with low or absent TPMT enzyme activity

A

True (neutropenia, and rarely agranulocytosis and pancytopenia)

45
Q

Patients on AZA are at a higher risk of infection secondary to their immunosuppressive state

A

True (increased infection rate typically seen in patients on higher doses of AZA or those who are on multiple immunosuppressive agents such as organ transplant recipients)

46
Q

The opportunistic infections seen in patients on AZA include HSV infections, HPV infections and scabetic infections

A

True (although true opportunistic infections are uncommon for dermatologic indications)

47
Q

AZA is found in breast milk and colostrum and is not recommended in breast feeding women

48
Q

Caution is advised when administering live vaccines to immunosuppressed patients (such as those on AZA), as a potential atypical response may theoretically occur

49
Q

The attenuated/killed virus vaccine of hepatitis B administered to patients on AZA and corticosteroids (and hence immunosuppressed) has shown a decreased response

50
Q

AZA may potentially very rarely cause a drug-induced hypersensitivity syndrome

A

True (very similar to the anticonvulsant hypersensitivity syndrome, and the cutaneous presentation is diverse)

51
Q

The rare drug-induced hypersensitivity reaction from AZA typically develop between 1 and 4 weeks after starting therapy

A

True (and more common in patients who are simultaneously receiving CsA or MTX therapy)

52
Q

The rare drug-induced hypersensitivity reaction from AZA is more common in patients who are simultaneously receiving CsA or MTX therapy

53
Q

Rechallenge of patients who have had a hypersensitivity reaction to AZA is contraindicated as this may cause a life-threatening reaction

54
Q

The most common adverse effects of AZA are GI including nausea, vomiting and diarrhoea

A

True (often present between the 1st and 10th days of therapy)

55
Q

The GI adverse effects of AZA including nausea, vomiting and diarrhoea often present between the 1st and 10th days of therapy

56
Q

Reducing the dose of AZA often alleviates the GI adverse effect symptoms of nausea, vomiting and diarrhoea

A

True (dividing the dose and taking AZA with food also helps to alleviate these symptoms)

57
Q

Dividing the dose of AZA often alleviates the GI adverse effect symptoms of nausea, vomiting and diarrhoea

A

True (reducing the dose and taking AZA with food also helps to alleviate these symptoms)

58
Q

Taking AZA with food often alleviates the GI adverse effect symptoms of nausea, vomiting and diarrhoea

A

True (reducing or dividing the dose also helps to alleviate these symptoms)

59
Q

Pancreatitis has rarely been reported in patients taking AZA

60
Q

Chronic administration of AZA has been associated with uncommon but life-threatening hepatic damage

A

True (LFT should be monitored throughout the length of treatment regardless of TPMT status)
N.B. MTX and systemic retinoids also causes liver toxicity

61
Q

Routine monitoring of LFT (transaminases) is of significant importance in patients receiving AZA, regardless of TPMT status

A

True (as chronic administration of AZA has been associated with life-threatening hepatic damage, though this is uncommon)

62
Q

The dose of AZA should be reduced in renal impairment

63
Q

TPMT assay does not need to be repeated subsequent to baseline determination

A

True (enzyme function guides dosing strategy as this provides an indication for patient risk of immunosuppression and myelosuppression)

64
Q

The best studied dermatologic uses of AZA are for the treatment of immunobullous diseases, most notably Pemphigus vulgaris and bullous pemphigoid

65
Q

The most important drug interaction occurs between AZA and allopurinol

A

True (allopurinol inhibits the xanthine oxidase degradative pathway and co-administration of allopurinol with AZA results in increased production of 6-TG active metabolites as more 6-MP is shifted to the anabolic HGPRT pathway, with excessive immunosuppression and increased risk for myelosuppression)

66
Q

5 other drug categories can potentially interact with AZA:

(1) ACE-inhibitors
(2) warfarin
(3) sulfasalazine
(4) neuromuscular blocker pancuronium
(5) other myelosuppressive drugs

67
Q

ACE-inhibitors with AZA may increase the risk of leukopenia due to increased myelosuppression

68
Q

A significant increase in warfarin dose may be required in patients on AZA as AZA may reduce the anticoagulant effect

69
Q

Sulfasalazine inhibits TPMT activity, and thus may potentiate AZA toxicity

70
Q

AZA may reduce the efficacy or reverse the neuromuscular blockade of pancuronium

A

True (may require an increased dose of this paralytic agent)

71
Q

Concomitant use of other known myelosuppressive agents I.e. MTX should be avoided with AZA as these potentiate the myelosuppressive effect

A

True (AZA itself is myelosuppressive)

72
Q

Concomitant AZA and MTX may cause plasma levels of 6-MP to be increased and potentiate increased myelosuppression

A

True (more 6-MP for the anabolic HGPRT pathway yielding more 6-TG)

73
Q

AZA may decrease plasma levels of CsA

Derm Pharm 2020 (47 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions